PSI-7977是核苷酸类似物,可用于慢性HCV感染。
Sofosbuvir (PSI-7977, GS-7977) is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
~100 μM
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Murakami E, et al. J Biol Chem, 2010, 285(45), 34337-34347.
分子式 C22H29FN3O9P |
分子量 529.45 |
CAS号 1190307-88-0 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 100 mg/mL |
Water 10 mg/mL |
Ethanol 100 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01994486 | Hepatitis C, Chronic | Drug: Telaprevir and Sofosbuvir | University of Florida|Vertex Pharmaceuticals Incorporated | Phase 2 | 2013-12-01 | 2015-02-20 |
NCT02907996 | Hepatitis C Virus | Drug: Sofosbuvir | Gilead Sciences | 2016-09-09 | 2017-03-16 | |
NCT02624063 | Hepatitis C, Chronic | Drug: Daclatasvir + Sofosbuvir|Drug: Simeprevir + Sofosbuvir | Federal University of So Paulo | Phase 4 | 2015-12-01 | 2017-02-17 |
NCT02206932 | Hepatitis C, Chronic|HIV CDC Category A1 | Drug: Sofosbuvir + Simeprevir | University of California, San Francisco|Janssen Scientific Affairs, LLC | Phase 4 | 2014-11-21 | |
NCT03032666 | Thalassemia|Hepatitis C | Drug: sofosbuvir/velpatasvir | Ala'a Sharara|Gilead Sciences|American University of Beirut Medical Center | Phase 4 | 2017-03-25 | 2017-02-27 |
NCT02576314 | Chronic Hepatitis C Infection | Drug: sofosbuvir and daclatasvir|Drug: ledipasvir/sofosbuvir | Humanity & Healthy GI and Liver Centre|Beijing 302 Hospital | Phase 3 | 2015-05-01 | 2017-01-15 |
NCT02783976 | HCV Infection | Drug: Sovaldi | Gilead Sciences | 2016-10-28 | 2017-02-22 | |
NCT02128542 | Hepatitis C Virus Infection | Drug: Sofosbuvir|Drug: RBV | Gilead Sciences | Phase 4 | 2014-06-01 | 2016-06-21 |
NCT03069001 | HCV | Drug: Sofosbuvir-Simeprevir|Drug: Sofosbuvir-Ribavirin | Ain Shams University | Phase 4 | 2015-06-01 | 2017-02-27 |
NCT01910636 | Hepatitis C | Drug: Sofosbuvir|Drug: RBV | Gilead Sciences | Phase 3 | 2013-02-01 | 2015-03-13 |
NCT02336139 | Hepatitis C | Drug: Sofosbuvir (SOF)/GS-5816 | Kirby Institute | Phase 2 | 2016-03-01 | 2016-05-15 |
NCT02702739 | Liver Cirrhosis | Drug: Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks | Azienda Ospedaliera San Camillo Forlanini | Phase 4 | 2015-01-01 | 2016-03-08 |
NCT03063879 | Hepatitis C, Chronic|Chronic Renal Failure | Drug: Sofosbuvir 400 mg and daclatasvir 60 mg | Tehran University of Medical Sciences|Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|Isfahan University of Medical Sciences|Tabriz University of Medical Sciences | Phase 4 | 2017-03-01 | 2017-02-23 |
NCT02250807 | Chronic Hepatitis C|Genotype 4 Chronic Hepatitis C | Drug: Simeprevir|Drug: Sofosbuvir | Janssen R&D Ireland | Phase 3 | 2015-01-01 | 2016-09-28 |
NCT02125500 | Viral Hepatitis C|HIV | Drug: Sofosbuvir/Ledipasvir fixed dose | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Phase 2 | 2014-09-01 | 2016-01-04 |
NCT02114151 | Hepatitis C Virus Infection | Drug: Simeprevir|Drug: Sofosbuvir | Janssen Infectious Diseases BVBA | Phase 3 | 2014-04-01 | 2016-03-07 |
NCT02156570 | Hepatitis C | Drug: Sofosbuvir and ribavirin | Kirby Institute | Phase 4 | 2014-10-01 | 2016-10-19 |
NCT02491450 | Healthy | Drug: Heterosofir|Drug: Sovaldi | Genuine Research Center, Egypt|Pharmed Healthcare, Egypt | Phase 1 | 2015-02-01 | 2015-07-02 |
NCT02961426 | Hepatitis C | Drug: sofosbuvir | Drugs for Neglected Diseases|Ministry of Health, Malaysia | Phase 2|Phase 3 | 2016-09-01 | 2016-11-08 |
NCT02074514 | Chronic HCV Infection | Drug: Sofosbuvir|Drug: RBV | Gilead Sciences | Phase 3 | 2014-03-01 | 2016-09-02 |
NCT02551861 | Hepatitis C | Drug: Daclatasvir|Drug: Sofosbuvir|Drug: Ribavirin | Bristol-Myers Squibb | Phase 2 | 2015-12-01 | 2016-01-14 |
NCT02253550 | Chronic Hepatitis C | Drug: Simeprevir|Drug: Sofosbuvir | Peter J. Ruane, M.D.|Janssen Scientific Affairs, LLC|Peter J. Ruane, M.D., Inc. | Phase 2 | 2014-10-01 | 2016-02-22 |
NCT03057847 | Hepatitis C, Chronic|Opioid-use Disorder | Drug: Sofosbuvir/Velpatasvir | University of Pittsburgh | Phase 4 | 2017-07-01 | 2017-02-15 |
NCT02804386 | Hepatitis C, Chronic | Drug: Sofosbuvir | PharmEvo Pvt Ltd | Phase 4 | 2016-06-01 | 2016-07-25 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们